About Lutris Pharma
Lutris Pharma is a company based in Tel Aviv (Israel) founded in 2016 by Antoni Ribas. Lutris Pharma has raised $30 million across 1 funding round from investors including Columbus Venture Partners, Pontifax Venture Capital and Peregrine. Lutris Pharma offers products and services including LUT014 and LUT-RD. Lutris Pharma operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Korro Bio, among others.
- Headquarter Tel Aviv, Israel
- Founders Antoni Ribas
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$30 M (USD)
in 1 rounds
-
Latest Funding Round
$30 M (USD), Series B
Jan 28, 2025
-
Investors
Columbus Venture Partners
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Lutris Pharma
Lutris Pharma offers a comprehensive portfolio of products and services, including LUT014 and LUT-RD.
Topical gel that reduces acneiform lesions from EGFR Inhibitors.
Gel treatment for radiation dermatitis in cancer patients.
Funding Insights of Lutris Pharma
Lutris Pharma has successfully raised a total of $30M through 1 strategic funding round. The most recent funding activity was a Series B round of $30 million completed in January 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Lutris Pharma
Lutris Pharma has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Columbus Venture Partners, Pontifax Venture Capital and Peregrine.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Columbus Venture Partners is focused on biotechnology investment funds.
|
Locked | Locked | Locked | |
|
Pontifax Venture Capital is focused on life sciences investments.
|
Locked | Locked | Locked | |
|
Peregrine is focused on healthcare innovation through strategic global investments.
|
Locked | Locked | Locked |
Investor details for Lutris Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Lutris Pharma
Investment portfolio details for Lutris Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Lutris Pharma
Detailed financials for Lutris Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Lutris Pharma Comparisons
Peer comparison for Lutris Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Lutris Pharma
Lutris Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Korro Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
RNA-editing technologies are provided for precision medicine applications.
|
|
| Locked | Locked | Locked |
Dental implants and regenerative dentistry products are developed.
|
Detailed competitors of Lutris Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Lutris Pharma
Complete news archive for Lutris Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lutris Pharma
Lutris Pharma was founded in 2016 and raised its 1st funding round 9 years after it was founded.
Lutris Pharma is headquartered in Tel Aviv, Israel.
Noa Shelach is the current CEO of Lutris Pharma.
Lutris Pharma is a funded company, having raised a total of $30M across 1 funding round to date.
Lutris Pharma was founded in 2016 in Tel Aviv, Israel, within the pharmaceutical sector. Focus is placed on developing EGFR inhibitors for anti-cancer treatment, aimed at minimizing dose-limiting dermal toxicity. The proprietary small molecule LUT014, a B-Raf-based inhibitor, is being advanced to reduce acneiform lesions and is currently in phase 1 clinical trials. Operations center on oncology drug innovation.
Lutris Pharma's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Lutris Pharma offers LUT014 and LUT-RD.
Lutris Pharma has 4 investors. Key investors include Columbus Venture Partners, Pontifax Venture Capital, Peregrine, and aMoon.